Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. The companys products include BYETTA (exenatide) injection for the treatment of type 2 diabetes; and SYMLIN (pramlintide acetate) injection for the treatment of type 1 and type 2 diabetes. It also has research and development (R&D) programs in the therapeutic areas of diabetes and obesity. The companys R&D programs for diabetes include exenatide once weekly, exenatide once weekly pen, exenatide suspension formulation, exenatide nasal, and the exenatide transdermal patch. Its R&D programs for obesity comprise pramlintide/metreleptin combination therapy and PYY 3-36. The company markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It has collaboration agreements Eli Lilly and Company; Alkermes, Inc.; Takeda Pharmaceutical Company Limited; Biocon, Ltd.; and BioSeek, Inc. The company was founded in 1987 and is based in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for AMLN